Clinical Trial Update: Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain [Phase 2]

View source ↗

Summary

Phase 2 study of LX9211 in participants with diabetic peripheral neuropathic pain completed, reporting efficacy, safety, and pharmacokinetic data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes
• Diabetic Peripheral Neuropathy

Drugs mentioned

• LX9211

Snippet

Sponsor: Lexicon Pharmaceuticals | Conditions: Diabetic Peripheral Neuropathy, Diabetes | Phase 2 | Status: COMPLETED | Results posted: 2025-06-25